ATE501269T1 - Detektion von genmutationen mittels lna primer - Google Patents

Detektion von genmutationen mittels lna primer

Info

Publication number: ATE501269T1
Authority: AT; Austria
Prior art keywords: lna; nucleic acid; dna; nucleotide; oligonucleotides
Prior art date: 1999-03-18

Application number

AT00910583T

Other languages

English (en)

Inventor

Jan Skouv

Mogens Fenger

Mogens Jacobsen

Original Assignee

Exiqon As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-18

Filing date

2000-03-17

Publication date

2011-03-15

2000-03-17 Application filed by Exiqon As filed Critical Exiqon As

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE501269T1 publication Critical patent/ATE501269T1/de

Links

238000001514 detection method Methods 0.000 title 1
230000035772 mutation Effects 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
238000000034 method Methods 0.000 abstract 4
239000002773 nucleotide Substances 0.000 abstract 4
125000003729 nucleotide group Chemical group 0.000 abstract 4
108700028369 Alleles Proteins 0.000 abstract 3
108091034117 Oligonucleotide Proteins 0.000 abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
108020004707 nucleic acids Proteins 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
102000039446 nucleic acids Human genes 0.000 abstract 3
239000000178 monomer Substances 0.000 abstract 2
108090000790 Enzymes Proteins 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
238000009396 hybridization Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Crystallography & Structural Chemistry (AREA)
Plant Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT00910583T 1999-03-18 2000-03-17 Detektion von genmutationen mittels lna primer ATE501269T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA199900383		1999-03-18
PCT/DK2000/000127 WO2000056916A2 (en)	1999-03-18	2000-03-17	Detection of mutations in genes by specific lna primers

Publications (1)

Publication Number	Publication Date
ATE501269T1 true ATE501269T1 (de)	2011-03-15

Family

ID=8092884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00910583T ATE501269T1 (de)	1999-03-18	2000-03-17	Detektion von genmutationen mittels lna primer

Country Status (14)

Country	Link
US (2)	US6316198B1 (de)
EP (1)	EP1161554B1 (de)
JP (1)	JP5095888B2 (de)
KR (1)	KR20020007331A (de)
CN (1)	CN1361829A (de)
AT (1)	ATE501269T1 (de)
AU (1)	AU3274500A (de)
CA (1)	CA2368169C (de)
DE (1)	DE60045706D1 (de)
HK (1)	HK1048339A1 (de)
IL (1)	IL145417A0 (de)
NZ (1)	NZ514104A (de)
RU (1)	RU2001128165A (de)
WO (1)	WO2000056916A2 (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6436640B1 (en) *	1999-03-18	2002-08-20	Exiqon A/S	Use of LNA in mass spectrometry
US6806363B1 (en) *	1999-04-16	2004-10-19	Mayo Foundation For Medical Education & Research	Cobalamin conjugates useful as antitumor agents
JP2003510017A (ja)	1999-06-22	2003-03-18	インビトロジェンコーポレイション	核酸の検出および識別のために改良されたプライマーおよび方法
AU2001247414A1 (en)	2000-03-14	2001-09-24	Active Motif	Oligonucleotide analogues, methods of synthesis and methods of use
US6962906B2 (en)	2000-03-14	2005-11-08	Active Motif	Oligonucleotide analogues, methods of synthesis and methods of use
WO2001083823A1 (en) *	2000-04-28	2001-11-08	Quantum Dot Corporation	Methods and compositions for polynucleotide analysis using generic capture sequences
EP2351855A1 (de) *	2000-09-26	2011-08-03	Duke University	RNA-Aptamere und Verfahren zu ihrer Identifizierung
TWI228512B (en) *	2000-10-25	2005-03-01	Mayo Foundation	Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US7211414B2 (en)	2000-12-01	2007-05-01	Visigen Biotechnologies, Inc.	Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
US20030077609A1 (en) *	2001-03-25	2003-04-24	Jakobsen Mogens Havsteen	Modified oligonucleotides and uses thereof
EP2070939B1 (de)	2001-05-25	2014-04-02	Duke University	Modulatoren von pharmakologischen Wirkstoffen
WO2002101041A1 (en) *	2001-06-12	2002-12-19	Takara Bio Inc.	Method of amplifying nucleic acid and method of detecting nucleotide polymorphism with the use of nucleotide analog
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7888324B2 (en)	2001-08-01	2011-02-15	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
WO2003018835A2 (en) *	2001-08-23	2003-03-06	Hvidovre Hospital	Method for rapid detection of haplotypes
US20060074034A1 (en) *	2001-09-17	2006-04-06	Collins Douglas A	Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
US20030165859A1 (en)	2001-10-23	2003-09-04	Invitrogen Corporation	Primers and methods for the detection and discrimination of nucleic acids
EP1463829A1 (de) *	2001-12-19	2004-10-06	Quantibact A/S	Verfahren und kit zur bestimmung einer mikrobenzahl
WO2003062793A2 (en) *	2002-01-24	2003-07-31	Pall Corporation	Analysis device
KR100440725B1 (ko) *	2002-06-20	2004-07-15	주식회사 그린진 바이오텍	비생물성 스트레스에 대한 단자엽 식물의 내성을증가시키는 방법
US20050053942A1 (en) *	2002-06-24	2005-03-10	Sakari Kauppinen	Methods and systems for detection and isolation of a nucleotide sequence
US20040219565A1 (en) *	2002-10-21	2004-11-04	Sakari Kauppinen	Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
US8206913B1 (en)	2003-03-07	2012-06-26	Rubicon Genomics, Inc.	Amplification and analysis of whole genome and whole transcriptome libraries generated by a DNA polymerization process
EP1706502A4 (de) *	2003-11-26	2007-05-23	Eppendorf Ag	Verfahren und zusammensetzungen zur in-vitro-amplifikation extrachromosomaler nukleinsäure
KR101185050B1 (ko)	2004-04-22	2012-10-04	레가도 바이오사이언스, 인코포레이티드	응고 인자의 개선된 모듈레이터
US20050287558A1 (en)	2004-05-05	2005-12-29	Crooke Rosanne M	SNPs of apolipoprotein B and modulation of their expression
US20060014183A1 (en) *	2004-06-10	2006-01-19	Pfundheller Henrik M	Extendable probes
US20060234277A1 (en) *	2005-03-31	2006-10-19	Amgen Inc.	Method for selectively blocking hemoglobin RNA amplification
JP5713377B2 (ja)	2005-12-28	2015-05-07	ザスクリプスリサーチインスティテュート	薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
CN101400806A (zh) *	2006-03-13	2009-04-01	和光纯药工业株式会社	突变基因的检测方法
US8007790B2 (en)	2006-04-03	2011-08-30	Stowers Institute For Medical Research	Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
DK2021472T3 (da)	2006-05-05	2011-09-19	Isis Pharmaceuticals Inc	Forbindelser og fremgangsmåder til modulering af genekspression
US9115389B2 (en) *	2006-06-30	2015-08-25	Rosetta Genomics Ltd.	Method for detecting a target nucleic acid comprising two portions using probes having a first portion complementary to the first portion of the target nucleic acid and a second portion substantially complementary to the second portion of the target nucleic acid
EP2484781B1 (de)	2006-08-01	2017-08-23	Applied Biosystems, LLC	Nachweis von Analyten und Nukleinsäuren
EP2069497B1 (de) *	2006-11-02	2013-08-14	University of Utah Research Foundation	Oligonukleotide für allelspezifische pcr
WO2009024834A2 (en)	2006-12-05	2009-02-26	Rosetta Genomics Ltd	Nucleic acids involved in viral infection
GB0703996D0 (en) *	2007-03-01	2007-04-11	Oxitec Ltd	Nucleic acid detection
GB0703997D0 (en) *	2007-03-01	2007-04-11	Oxitec Ltd	Methods for detecting nucleic sequences
RU2559536C2 (ru)	2007-03-24	2015-08-10	Джензим Корпорейшн	Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
US8138318B2 (en)	2007-09-13	2012-03-20	Abbott Laboratories	Hepatitis B pre-S2 nucleic acid
WO2009052301A1 (en) *	2007-10-16	2009-04-23	Regado Biosciences, Inc.	Steady-state subcutaneous administration of aptamers
US20090253121A1 (en) *	2008-04-04	2009-10-08	Micah Halpern	Method for amt-rflp dna fingerprinting
CA2739464C (en)	2008-10-03	2020-03-31	Curna, Inc.	Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
KR101866152B1 (ko)	2008-12-04	2018-06-08	큐알엔에이, 인크.	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
KR101829469B1 (ko)	2008-12-04	2018-03-30	큐알엔에이, 인크.	Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
MX2011005912A (es)	2008-12-04	2011-06-17	Opko Curna Llc	Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
WO2010093904A2 (en)	2009-02-12	2010-08-19	Curna, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2408919B1 (de)	2009-03-16	2017-10-18	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
US9107933B2 (en)	2009-03-16	2015-08-18	Isis Pharmaceuticals, Inc.	Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
EP2408920B1 (de)	2009-03-17	2017-03-08	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
WO2010129746A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2010129861A2 (en)	2009-05-08	2010-11-11	Curna, Inc.	Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
WO2010135329A2 (en)	2009-05-18	2010-11-25	Curna, Inc.	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (zh)	2009-05-22	2017-09-26	库尔纳公司	通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
CA2764683A1 (en)	2009-05-28	2010-12-02	Joseph Collard	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
JP5944311B2 (ja)	2009-06-16	2016-07-05	クルナ・インコーポレーテッド	コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
CN102612560B (zh)	2009-06-16	2017-10-17	库尔纳公司	通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
US8859515B2 (en)	2009-06-24	2014-10-14	Curna, Inc.	Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
CA2765815A1 (en)	2009-06-26	2010-12-29	Opko Curna, Llc	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US20120252869A1 (en)	2009-07-24	2012-10-04	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
JP6128848B2 (ja)	2009-08-05	2017-05-17	クルナ・インコーポレーテッド	インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
CA2770104C (en)	2009-08-11	2019-03-19	Opko Curna, Llc	Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
WO2011022606A2 (en)	2009-08-21	2011-02-24	Curna, Inc.	Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
KR101892760B1 (ko)	2009-08-25	2018-08-28	큐알엔에이, 인크.	ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
KR101802540B1 (ko)	2009-09-25	2017-11-28	큐알엔에이, 인크.	Ｆｌｇ의 발현 및 활성을 조절함으로써 필라그린(ｆｌｇ)에 관련된 질환의 치료
EP2494066B1 (de)	2009-10-27	2017-04-05	Swift Biosciences, Inc.	Bimolekulare primer
KR101851699B1 (ko)	2009-11-02	2018-04-24	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
WO2011084455A2 (en)	2009-12-16	2011-07-14	Opko Curna, Llc.	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
ES2661387T3 (es)	2009-12-23	2018-03-28	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
JP6031356B2 (ja)	2009-12-23	2016-11-24	カッパーアールエヌエー，インコーポレイテッド	Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
KR101838305B1 (ko)	2009-12-29	2018-03-13	큐알엔에이, 인크.	ＮＲＦ1(ＮｕｃｌｅａｒＲｅｓｐｉｒａｔｏｒｙＦａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
US8962585B2 (en)	2009-12-29	2015-02-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
DK2519632T3 (en)	2009-12-31	2018-07-23	Curna Inc	TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
EP2521784B1 (de)	2010-01-04	2017-12-06	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem interferonregulierungsfaktor 8 (irf8) mittels hemmung des natürlichen antisense-transkripts gegen irf8
CN102822342B (zh)	2010-01-06	2017-05-10	库尔纳公司	通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
US9200277B2 (en)	2010-01-11	2015-12-01	Curna, Inc.	Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
CN102782135A (zh)	2010-01-25	2012-11-14	库尔纳公司	通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
WO2011103528A2 (en)	2010-02-22	2011-08-25	Opko Curna Llc	Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011104695A2 (en) *	2010-02-26	2011-09-01	GAMMAGENETICS Sàrl	Detection of kras mutation in exon 2 by allele specific real time quantitative pcr (as-qpcr)
WO2011104694A2 (en) *	2010-02-26	2011-09-01	GAMMAGENETICS Sàrl	Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes
CA2795145C (en)	2010-04-02	2019-01-22	Curna, Inc.	Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
KR101900962B1 (ko)	2010-04-09	2018-09-20	큐알엔에이, 인크.	섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CA2799207C (en)	2010-05-26	2019-03-26	Curna, Inc.	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
RU2620978C2 (ru)	2010-05-26	2017-05-30	Курна, Инк.	Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra
KR101914309B1 (ko)	2010-06-23	2018-11-02	큐알엔에이, 인크.	전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
US20120004132A1 (en) *	2010-07-02	2012-01-05	Affymetrix, Inc.	Detection of Nucleic Acids and Proteins
WO2012006551A2 (en)	2010-07-08	2012-01-12	The Brigham And Women's Hospital, Inc.	Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
NO2593547T3 (de)	2010-07-14	2018-04-14
CA2813901C (en)	2010-10-06	2019-11-12	Curna, Inc.	Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
JP6049623B2 (ja)	2010-10-22	2016-12-21	カッパーアールエヌエー，インコーポレイテッド	α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
US9416360B2 (en)	2010-11-05	2016-08-16	MiRagen Therapeutics, Inc.	Base modified oligonucleotides
US10000752B2 (en)	2010-11-18	2018-06-19	Curna, Inc.	Antagonat compositions and methods of use
WO2012071238A2 (en)	2010-11-23	2012-05-31	Opko Curna Llc	Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
AR084319A1 (es)	2010-12-15	2013-05-08	Miragen Therapeutics	INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
WO2012142003A2 (en)	2011-04-15	2012-10-18	Life Technologies Corporation	Chemical ligation
RU2620980C2 (ru)	2011-06-09	2017-05-30	Курна, Инк.	Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
CN103765212A (zh)	2011-06-27	2014-04-30	杰克逊实验室	治疗癌症和自体免疫性疾病的方法和组合物
US10583128B2 (en)	2011-09-06	2020-03-10	Curna, Inc.	Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
WO2013075079A1 (en) *	2011-11-17	2013-05-23	Rheonix, Inc.	System and methods for selective molecular analysis
CN102586433B (zh) *	2012-02-14	2014-01-29	北京科聆金仪生物技术有限公司	一种聋病易感基因12S rRNA 1494C＞T荧光检测试剂盒及其应用
EP2825648B1 (de)	2012-03-15	2018-09-05	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
EP2837695B1 (de) *	2012-04-12	2018-01-10	The University of Tokyo	Nucleinsäurequantifizierungsverfahren, detektionssonde, detektionssondensatz und nucleinsäuredetektionsverfahren
CN104685056A (zh)	2012-06-21	2015-06-03	米拉根医疗股份有限公司	包含锁核酸基序的基于寡核苷酸的抑制剂
WO2014134144A1 (en)	2013-02-28	2014-09-04	The General Hospital Corporation	Mirna profiling compositions and methods of use
CN105338998B (zh)	2013-03-15	2021-12-14	宾夕法尼亚大学理事会	口蹄疫病毒(fmdv)共有蛋白、其编码序列以及由其制造的疫苗
KR20150131365A (ko)	2013-03-15	2015-11-24	미라젠 세러퓨틱스 인코포레이티드	브리지드 바이사이클릭 뉴클레오시드
CN105188715B (zh)	2013-03-15	2018-12-25	米拉根医疗股份有限公司	Mir-145的锁定核酸抑制剂及其用途
US10758614B2 (en)	2014-06-09	2020-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health	Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2015191596A1 (en)	2014-06-09	2015-12-17	Biomed Valley Discoveries, Inc.	Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
US11034757B2 (en)	2014-06-09	2021-06-15	Biomed Valley Discoveries, Inc.	Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US10758613B2 (en)	2014-06-09	2020-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Intstitutes Of Health	Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
WO2015191610A2 (en)	2014-06-09	2015-12-17	Biomed Valley Discoveries, Inc.	Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
US11033620B2 (en)	2014-06-09	2021-06-15	Biomed Valley Discoveries, Inc.	Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
CN107636003A (zh)	2015-01-20	2018-01-26	米拉根医疗股份有限公司	miR‑92抑制剂及其用途
CN105039514A (zh) *	2015-06-02	2015-11-11	武汉友芝友医疗科技有限公司	人类braf基因v600e突变检测试剂盒
HK1254954A1 (zh)	2015-06-29	2019-08-02	Biomed Valley Discoveries, Inc.	Lpt-723和免疫检查点抑制剂组合物及其治疗方法
CN107012221A (zh) *	2016-10-14	2017-08-04	苏州艾达康医疗科技有限公司	基于阻断物的富集系统及其应用
WO2018226930A1 (en) *	2017-06-07	2018-12-13	President And Fellows Of Harvard College	Targeted expansion fluorescent in situ sequencing
AU2018309739B2 (en)	2017-07-31	2022-01-27	The Trustees Of Columbia University In The City Of New York	Compounds, Compositions, and Methods for Treating T-cell Acute Lymphoblastic Leukemia
US11629342B2 (en)	2017-10-17	2023-04-18	President And Fellows Of Harvard College	Cas9-based transcription modulation systems
US20210317461A1 (en)	2018-08-09	2021-10-14	Verseau Therapeutics, Inc.	Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
EP3846824B1 (de)	2018-09-07	2025-06-18	The General Hospital Corporation	Zusammensetzungen und verfahren zur immuncheckpoint-inhibition
WO2022140126A1 (en)	2020-12-21	2022-06-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Dna vector and uses thereof for detecting hiv and siv
WO2024010841A2 (en)	2022-07-06	2024-01-11	Molecular Axiom, Llc	Compositions and methods for treating pancreatic cancer
EP4577650A1 (de)	2022-08-25	2025-07-02	Life Edit Therapeutics, Inc.	Chemische modifikation von guide-rnas mit verriegelter nukleinsäure zur rna-geführten nukleasevermittelten geneditierung
CN120350100A (zh) *	2024-01-19	2025-07-22	柏锘（上海）医疗科技有限公司	检测核酸低频突变的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
DE3813278A1 (de)	1988-01-12	1989-07-20	Boehringer Mannheim Gmbh	Verfahren zum nachweis von nukleinsaeuren
CA1340807C (en) *	1988-02-24	1999-11-02	Lawrence T. Malek	Nucleic acid amplification process
IE61148B1 (en) *	1988-03-10	1994-10-05	Ici Plc	Method of detecting nucleotide sequences
DE68916671T2 (de)	1988-03-18	1995-03-02	Baylor College Medicine	Mutationsnachweis durch kompetitiven Oligonukleotid-Priming.
AU3539089A (en) *	1988-04-08	1989-11-03	Salk Institute For Biological Studies, The	Ligase-based amplification method
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
DE4129653A1 (de)	1991-09-06	1993-03-11	Boehringer Mannheim Gmbh	Verfahren zum nachweis aehnlicher nukleinsaeuren
ES2103918T3 (es)	1991-10-17	1997-10-01	Ciba Geigy Ag	Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
IL111857A (en) *	1994-12-02	1999-09-22	Intelligene Ltd	Detection of nucleic acid sequences
WO1996020212A2 (en) *	1994-12-28	1996-07-04	Buchardt, Dorte	Peptide nucleic acid incorporating a chiral backbone
ES2153097T3 (es)	1995-04-07	2001-02-16	Mogens Havsteen Jakobsen	Procedimiento de inmovilizacion fotoquimica de ligandos usando quinonas.
US6043060A (en)	1996-11-18	2000-03-28	Imanishi; Takeshi	Nucleotide analogues
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2303299C (en)	1997-09-12	2016-02-23	Exiqon A/S	Oligonucleotide analogues

2000
- 2000-03-17 JP JP2000606775A patent/JP5095888B2/ja not_active Expired - Lifetime
- 2000-03-17 NZ NZ514104A patent/NZ514104A/xx not_active Application Discontinuation
- 2000-03-17 CN CN00807543A patent/CN1361829A/zh active Pending
- 2000-03-17 EP EP00910583A patent/EP1161554B1/de not_active Expired - Lifetime
- 2000-03-17 KR KR1020017011764A patent/KR20020007331A/ko not_active Withdrawn
- 2000-03-17 AU AU32745/00A patent/AU3274500A/en not_active Abandoned
- 2000-03-17 RU RU2001128165/13A patent/RU2001128165A/ru unknown
- 2000-03-17 DE DE60045706T patent/DE60045706D1/de not_active Expired - Lifetime
- 2000-03-17 CA CA2368169A patent/CA2368169C/en not_active Expired - Lifetime
- 2000-03-17 IL IL14541700A patent/IL145417A0/xx unknown
- 2000-03-17 HK HK02107778.1A patent/HK1048339A1/zh unknown
- 2000-03-17 WO PCT/DK2000/000127 patent/WO2000056916A2/en not_active Ceased
- 2000-03-17 AT AT00910583T patent/ATE501269T1/de not_active IP Right Cessation
- 2000-03-18 US US09/528,115 patent/US6316198B1/en not_active Expired - Lifetime
2001
- 2001-08-16 US US09/932,058 patent/US20020115080A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2001128165A (ru)	2004-03-27
US20020115080A1 (en)	2002-08-22
AU3274500A (en)	2000-10-09
CA2368169C (en)	2012-07-10
EP1161554B1 (de)	2011-03-09
IL145417A0 (en)	2002-06-30
NZ514104A (en)	2001-09-28
JP2002539801A (ja)	2002-11-26
DE60045706D1 (de)	2011-04-21
US6316198B1 (en)	2001-11-13
JP5095888B2 (ja)	2012-12-12
WO2000056916A2 (en)	2000-09-28
WO2000056916A3 (en)	2001-02-08
EP1161554A2 (de)	2001-12-12
CA2368169A1 (en)	2000-09-28
CN1361829A (zh)	2002-07-31
KR20020007331A (ko)	2002-01-26
HK1048339A1 (zh)	2003-03-28

Legal Events

Date	Code	Title	Description
2011-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60045706D1 (de)	2011-04-21	Detektion von genmutationen mittels lna primer
Weber	1990	Informativeness of human (dC-dA) n·(dG-dT) n polymorphisms
Daniel et al.	2015	A SNaPshot of next generation sequencing for forensic SNP analysis
Hou et al.	2001	Allele sequences of six new Y-STR loci and haplotypes in the Chinese Han population
Martins-Lopes et al.	2001	Detection of single nucleotide mutations in wheat using single strand conformation polymorphism gels
CA2599647C (en)	2013-07-16	Processes using dual specificity oligonucleotide and dual specificity oligonucleotide
ATE427999T1 (de)	2009-04-15	Erkennung von nukleinsaurepolymorphismen
EP0972078B1 (de)	2005-06-01	Iterative resequenzierung
EP1061135A3 (de)	2003-06-25	Verfahren und Oligonukleotide zum Nachweis von Nukleinsäuresequenzvariationen
WO1997035033A1 (en)	1997-09-25	Method for determining the nucleotide sequence of a polynucleotide
CA2468754A1 (en)	2003-06-19	Annealing control primer and its uses
US20100092972A1 (en)	2010-04-15	Assay for gene expression
WO2003016565A3 (en)	2003-08-21	Dna sequence analysis
EP2217719A1 (de)	2010-08-18	Oligonukleotide und deren verwendungen
HK1216653A1 (zh)	2016-11-25	多重核酸檢測方法
WO2002083955A1 (en)	2002-10-24	Methods and compositions for nucleotide analysis
Zhang et al.	2003	Single-base discrimination mediated by proofreading 3′ phosphorothioate-modified primers
WO1999039004A1 (en)	1999-08-05	Iterative resequencing
Zhang et al.	2003	Efficient mutagenesis method for producing the templates of single nucleotide polymorphisms
KR101581388B1 (ko)	2015-12-30	다형 검출용 프로브, 다형 검출 방법, 약효 판정 방법 및 다형 검출용 시약 키트
Rudolph et al.	2002	Determination of melting temperature for variant detection using dHPLC: a comparison between an empirical approach and DNA melting prediction software
Hou et al.	1994	Population genetics of three STR polymorphisms in a Chinese population
Hou et al.	2002	Typing Y chromosome STR haplotypes using redesigned primers
Reichenpfader et al.	1999	Characterization of a highly variable short tandem repeat polymorphism at the D2S1242 locus
Curran et al.	2002	Validation of single nucleotide polymorphism quantification in pooled DNA samples with SNaPIT™: A glycosylase-mediated methods for polymorphism detection method